Scinai Immunotherapeutics Ltd ADR (SCNI) Stock Price, Quote & News

Company Profile

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturi...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 930 2529

Fax: 972 8 930 2531

Website: www.scinai.com

Address:

Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus, Jerusalem, Israel

Richard_Roma Jun. 10 at 1:06 PM

$SCNI pinksheet ready

0 · Reply

stockanalysis_ Jun. 9 at 9:06 PM

After Hours Losers: $YOUL $ITP $EPSM $PMI $SCNI View this screener: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading

0 · Reply

Richard_Roma Jun. 9 at 3:43 PM

$SCNI the CEO and execs thanks you for your generous contributions keeping this turd afloat

0 · Reply

focafoca99 Jun. 8 at 5:13 PM

$SCNI announced its annual meeting set for June 16, 2026, with a proxy proposal to extend Chairman Mark Germain's services agreement.

1 · Reply

Kesiya Jun. 1 at 2:02 AM

$SCNI Buy now"

1 · Reply

M105 Jun. 1 at 1:42 AM

$BDRX $IBM $NTCL $OLOX $SCNI it’s 309%+ and counting now, that’s why the dumb bear here is trying to make people believe his lies 😂😂😂😂 OLOX will bankrupt a lot of bears today 😂😂😂😂

0 · Reply

Kesiya Jun. 1 at 1:38 AM

#6 $SCNI /A Fee 217.52% Availa 150000 Float:8.91M /Watchlist $NTCL $OLOX $BDRX $IBM

0 · Reply

luckysupernova May. 22 at 2:34 AM

$SCNI

0 · Reply

Richard_Roma May. 20 at 4:55 PM

$SCNI should seek pink sheet listing and gtfo of nasdaq

0 · Reply

Bulltrader988 May. 20 at 2:20 PM

$SCNI 👃👀 https://www.stocktitan.net/news/SCNI/scinai-biopharma-services-appoints-eilon-elmalem-as-site-head-of-zfrv0he7xla3.html

1 · Reply

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Wed, 20 May 2026 07:00:00 -0400 - 21 days ago

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Fri, 15 May 2026 08:05:00 -0400 - 26 days ago

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

2026-04-25T00:50:00.000Z - 6 weeks ago

Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?

Fri, 24 Apr 2026 10:25:04 -0400 - 6 weeks ago

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

2026-04-24T12:16:55.000Z - 6 weeks ago

Scinai Immunotherapeutics announces $2.61M private placement

Fri, 24 Apr 2026 08:00:00 -0400 - 6 weeks ago

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

2026-04-06T11:17:23.000Z - 2 months ago

Scinai Immunotherapeutics completes strategic reorganization

2026-04-06T11:10:47.000Z - 2 months ago

Scinai Immunotherapeutics targets $5M in CDMO revenue in 2026

Mon, 06 Apr 2026 07:00:00 -0400 - 2 months ago

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Wed, 01 Apr 2026 07:35:00 -0400 - 2 months ago

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

2026-03-19T12:08:05.000Z - 2 months ago

Scinai Immunotherapeutics highlights expanded CDMO platform

Mar 19, 2026, 7:50 AM EDT - 2 months ago

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Mar 16, 2026, 4:05 PM EDT - 3 months ago

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

2026-03-02T14:30:59.000Z - 3 months ago

Scinai Immunotherapeutics signs second amendment to PinCell option agreement

Mar 2, 2026, 9:20 AM EST - 3 months ago

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Feb 25, 2026, 8:11 AM EST - 3 months ago

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Feb 17, 2026, 7:00 AM EST - 4 months ago

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Jan 7, 2026, 7:00 AM EST - 5 months ago

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Dec 2, 2025, 8:50 AM EST - 6 months ago

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

2025-10-06T11:40:52.000Z - 8 months ago

Scinai Immunotherapeutics awarded grant from Israel Innovation Authority

Oct 6, 2025, 7:30 AM EDT - 8 months ago

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

2025-07-29T11:31:12.000Z - 11 months ago

Scinai Immunotherapeutics’ PC111 featured in peer-reviewed publication

Jul 29, 2025, 7:15 AM EDT - 11 months ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

May 30, 2025, 7:00 AM EDT - 1 year ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 7, 2025, 4:01 PM EDT - 1 year ago

Scinai Announces Annual Financial Results for 2024

May 1, 2025, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Mar 27, 2025, 9:25 AM EDT - 1 year ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

2025-03-05T12:37:36.000Z - 1 year ago

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

Mar 5, 2025, 7:30 AM EST - 1 year ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

2025-03-04T22:30:58.000Z - 1 year ago

Scinai Immunotherapeutics files to sell 3.02M ADS for holders

Jan 6, 2025, 7:31 AM EST - 1 year ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Dec 16, 2024, 9:25 AM EST - 1 year ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 5, 2024, 8:25 AM EST - 1 year ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 1 year ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 22, 2024, 7:15 AM EST - 1 year ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Oct 31, 2024, 6:59 AM EDT - 1 year ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 9, 2024, 11:12 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

2024-08-29T10:35:55.000Z - 1 year ago

Scinai Immunotherapeutics regains compliance with Nasdaq

Aug 29, 2024, 6:31 AM EDT - 1 year ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 20, 2024, 9:30 AM EDT - 1 year ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

2024-07-23T11:13:35.000Z - 2 years ago

Scinai Immunotherapeutics’ IL-17 nanoAb receives positive regulatory feedback

Jul 23, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 15, 2024, 12:31 PM EDT - 2 years ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

2024-07-15T11:10:01.000Z - 2 years ago

Scinai Immunotherapeutics’ psoriasis candidate shows efficacy in study

Jul 15, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

2024-07-08T12:18:12.000Z - 2 years ago

Scinai Immunotherapeutics receives updated LOI from EIB

Jul 8, 2024, 8:14 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 3, 2024, 9:32 AM EDT - 2 years ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

2024-07-02T12:31:36.000Z - 2 years ago

Scinai Immunotherapeutics reports Q1 EPS ($0.001c) vs ($0.003) last year

Jul 2, 2024, 8:12 AM EDT - 2 years ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

2024-06-07T11:02:39.000Z - 2 years ago

Scinai Immunotherapeutics regains Nasdaq compliance

Jun 7, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

May 24, 2024, 4:01 PM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 15, 2024, 4:01 PM EDT - 2 years ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 6, 2024, 9:21 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Richard_Roma Jun. 10 at 1:06 PM

$SCNI pinksheet ready

0 · Reply

stockanalysis_ Jun. 9 at 9:06 PM

After Hours Losers: $YOUL $ITP $EPSM $PMI $SCNI View this screener: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading

0 · Reply

Richard_Roma Jun. 9 at 3:43 PM

$SCNI the CEO and execs thanks you for your generous contributions keeping this turd afloat

0 · Reply

focafoca99 Jun. 8 at 5:13 PM

$SCNI announced its annual meeting set for June 16, 2026, with a proxy proposal to extend Chairman Mark Germain's services agreement.

1 · Reply

Kesiya Jun. 1 at 2:02 AM

$SCNI Buy now"

1 · Reply

M105 Jun. 1 at 1:42 AM

0 · Reply

Kesiya Jun. 1 at 1:38 AM

#6 $SCNI /A Fee 217.52% Availa 150000 Float:8.91M /Watchlist $NTCL $OLOX $BDRX $IBM

0 · Reply

luckysupernova May. 22 at 2:34 AM

$SCNI

0 · Reply

Richard_Roma May. 20 at 4:55 PM

$SCNI should seek pink sheet listing and gtfo of nasdaq

0 · Reply

Bulltrader988 May. 20 at 2:20 PM

$SCNI 👃👀 https://www.stocktitan.net/news/SCNI/scinai-biopharma-services-appoints-eilon-elmalem-as-site-head-of-zfrv0he7xla3.html

1 · Reply

Bulltrader988 May. 15 at 12:15 PM

$SCNI "...today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands..." 👃👀 https://www.stocktitan.net/news/SCNI/scinai-immunotherapeutics-to-lead-strategic-roundtable-discussion-on-z2gdfmc056rs.html

1 · Reply

focafoca99 May. 12 at 9:53 PM

$SCNI scheduled its annual shareholders meeting for June 16, 2026.

0 · Reply

MysticMorpheus May. 9 at 8:22 PM

Make sure to keep eyes on ticker AMS📈 for next week! It does not get better than this in small caps. AMS has the recipe to see a massive run! ✅ No current dilution ✅ Volume picking up ✅ Momentum building ✅ Clean chart setup ✅ Major contract locked through 2033 ✅ Improving fundamentals $SCNI $SPRC $ONEG .. $SVRE ..1

0 · Reply

CrumbEater May. 8 at 7:46 PM

$SCNI https://www.stocktitan.net/sec-filings/SCNI/6-k-scinai-immunotherapeutics-ltd-current-report-foreign-issuer-a6b6d38f512a.html

0 · Reply

focafoca99 May. 8 at 11:40 AM

$SCNI declares it completed the acquisition of Recipharm Israel and filed audited and pro forma financial statements of the new subsidiary.

0 · Reply

SuperGreenToday Apr. 30 at 8:45 PM

$SCNI

0 · Reply

Richard_Roma Apr. 29 at 1:37 PM

$SCNI of course another placement to dilute shateholders and provide a comfortable living to execs for non-performance.

0 · Reply

Bulltrader988 Apr. 28 at 6:55 PM

$SCNI From yesterdays filling: " ...Closing Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first Trading Day following the date hereof if this Agreement is entered into before 4 p.m. Eastern time, or no later than the second Trading Day following the date hereof, if this Agreement is entered at or after 4 p.m. Eastern time...." 👃👀 https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319982642&type=HTML&symbol=SCNI&cdn=27e649d3764bf88cf25ce26b2bd729ff&companyName=Scinai+Immunotherapeutics+Ltd.&formType=6-K&formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&dateFiled=2026-04-27

0 · Reply

NewbieStar Apr. 28 at 2:13 AM

$SCNI just got in. Looking at exiting at $5

1 · Reply

Richard_Roma Apr. 27 at 8:40 PM

$SCNI are you not entertained? This flaming dumpster will probably be up for another placement soon, as execs need to maintain their higher standard of living.

0 · Reply

rbobby25 Apr. 27 at 3:28 PM

$SCNI - just jumped into this stock and bought 5000 shares to start. See how today/this week rolls. Looks promising for a bit of a lift off upwards.

1 · Reply

Market Cap	1.61M
Revenue (ttm)	1.31M
Net Income (ttm)	-8.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.35%
Debt to Equity Ratio	0.04

Volume	340,600
Avg Vol	4,261,522
Day's Range	N/A - N/A
Shares Out	3.96M
Stochastic %K	7%
Beta	2.06
Analysts	Strong Buy
Price Target	$8.00